Targets › GZMB
2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Abundant protease in the cytosolic granules of cytotoxic T-cells and NK-cells which activates caspase-independent pyroptosis when delivered into the target cell through the immunological synapse. It cleaves after Asp. (UniProt, P10144)
Open in Phaseline: the race on GZMB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Rahul Aggarwal | 64Cu-GRIP B Copper-64 labeled granzyme B targeting radiotracer for PET imaging | GZMB | Phase 1 | Prostate Cancer | Dec 2026 |
| Michael Randall | 64Cu-GRIP B 64-copper labeled granzyme B-targeting peptide for PET imaging | GZMB | Phase 1 | Non Hodgkin Lymphoma | Jan 2027 |
Prostate Cancer (1) Non Hodgkin Lymphoma (1)
small molecule (1), protein or peptide (1)
Rahul Aggarwal (1) Michael Randall (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.